Literature DB >> 11878764

Selection of phage-displayed peptides recognised by monoclonal antibodies directed against the lipopolysaccharide of Brucella.

P Mertens1, D Walgraffe, T Laurent, N Deschrevel, J J Letesson, X De Bolle.   

Abstract

Panning and screening of various phage display libraries with monoclonal antibodies (mAbs) directed against the O-chain of the lipopolysaccharide (LPS) of Brucella sp. allowed the identification of peptidic mimotopes of some O-chain epitopes. Four mAbs were tested. The A76-12G12 mAb, which is specific for LPS of all strains of Brucella, either A- or M-dominant, did not yield any peptidic mimotope, despite a specific yield enrichment during the rounds of panning. The B66-4F9 mAb, that recognises an epitope common to both Brucella sp. and Yersinia enterocilitca O:9 strains, allowed the selection of only one phage clone that was shown to be an antigenic but not immunogenic mimotope. The B66-2C8 and A15-6B3 mAbs, respectively, specific for the LPS of A-dominant and M-dominant Brucella sp., yielded several sequences, which allowed the determination of consensus sequences. These consensus will be of high interest for the construction of second generation libraries. For the best binding peptides, competition with LPS for the binding to the mAb is detected, which suggests that the peptides bind to the paratope of the mAb. The phages selected from the libraries were used to immunise mice, and a weak antibody response directed against LPS has been observed for some peptides. These data suggest that a subset of the selected peptides are immunogenic mimotopes of the LPS epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11878764     DOI: 10.3109/08830180109043033

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  7 in total

Review 1.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen.

Authors:  Ayman Al-Mariri; Anne Tibor; Pascal Lestrate; Pascal Mertens; Xavier De Bolle; Jean-Jacques Letesson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

3.  Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.

Authors:  Till Seiler; Manuela Woelfle; Sophia Yancopoulos; Rosa Catera; Wentian Li; Katerina Hatzi; Carol Moreno; Marcela Torres; Santanu Paul; Hartmut Dohner; Stephan Stilgenbauer; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  Blood       Date:  2009-08-18       Impact factor: 22.113

4.  Differentiation between serological responses to Brucella suis and Yersinia enterocolitica serotype O:9 after natural or experimental infection in pigs.

Authors:  G Jungersen; V Sørensen; S B Giese; J A Stack; U Riber
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

5.  Development and characterization of monoclonal antibodies and aptamers against major antigens of Mycobacterium avium subsp. paratuberculosis.

Authors:  John P Bannantine; Thomas J Radosevich; Judith R Stabel; Srinand Sreevatsan; Vivek Kapur; Michael L Paustian
Journal:  Clin Vaccine Immunol       Date:  2007-03-07

Review 6.  Arming Filamentous Bacteriophage, a Nature-Made Nanoparticle, for New Vaccine and Immunotherapeutic Strategies.

Authors:  Rossella Sartorius; Luciana D'Apice; Antonella Prisco; Piergiuseppe De Berardinis
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

Review 7.  Phage display as a promising approach for vaccine development.

Authors:  Leili Aghebati-Maleki; Babak Bakhshinejad; Behzad Baradaran; Morteza Motallebnezhad; Ali Aghebati-Maleki; Hamid Nickho; Mehdi Yousefi; Jafar Majidi
Journal:  J Biomed Sci       Date:  2016-09-29       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.